Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 14c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q4 EPS of ($0.45), $0.14 worse than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• IREN (IREN) Reiterated at Market Outperform by Citizens as Cloud Business Gains Momentum
• Gap, Inc. (GAP) PT Raised to $42 at UBS
• The Gap, Inc. (GAP) Tops Q2 EPS by 3c